The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats

Neuropsychopharmacology

Volumn 36, Issue 3, 2011, Pages 664-676

  Hao, Shuanglin ^a,b,c   Liu, Shue ^a,b,c   Zheng, Xuexing ^a,b,c   Zheng, Wenwen ^a,b,c   Ouyang, Handong ^a,b   Mata, Marina ^a,b   Fink, David J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

gene therapy; morphine withdrawal; PAG; soluble TNF receptor; TNFa

Indexed keywords

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NALOXONE; PROTEIN FOS; PROTEIN P55; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DOWN REGULATION; HERPES SIMPLEX VIRUS; IMMUNOREACTIVITY; MICROINJECTION; MORPHINE ADDICTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

ANIMALS; BEHAVIOR, ANIMAL; CREB-BINDING PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; MALE; MICROINJECTIONS; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; ONCOGENE PROTEINS V-FOS; PERIAQUEDUCTAL GRAY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651401018     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.197     Document Type: Article

References (85)

1. Antunes Bras JM, Epstein AL, Bourgoin S, Hamon M, Cesselin F, Pohl M (1998). Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 70: 1299-1303.
2. Bains JS, Oliet SH (2007). Glia: they make your memories stick!. Trends Neurosci 30: 417-424.
3. Bandler R, Shipley MT (1994). Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci 17: 379-389.
4. Barrot M, Olivier JD, Perrotti LI, DiLeone RJ, Berton O, Eisch AJ et al (2002). CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci USA 99: 11435-11440.
5. Blendy JA, Maldonado R (1998). Genetic analysis of drug addiction: the role of cAMP response element binding protein. J Mol Med 76: 104-110.
6. Bozarth MA (1994). Physical dependence produced by central morphine infusions: an anatomical mapping study. Neurosci Biobehav Rev 18: 373-383.
7. Cami J, Farre M (2003). Drug addiction. N Engl J Med 349: 975-986.
8. Cao JL, He JH, Ding HL, Zeng YM (2005). Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent rats. Pain 118: 336-349.
9. Castilho VM, Borelli KG, Brandao ML, Nobre MJ (2008). Anxietylike symptoms induced by morphine withdrawal may be due to the sensitization of the dorsal periaqueductal grey. Physiol Behav 94: 552-562.
10. Chieng B, Christie MD (1996). Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. J Neurosci 16: 7128-7136.
11. Chieng B, Keay KA, Christie MJ (1995). Increased fos-like immunoreactivity in the periaqueductal gray of anaesthetised rats during opiate withdrawal. Neurosci Lett 183: 79-82.
12. Christie MJ, Williams JT, Osborne PB, Bellchambers CE (1997). Where is the locus in opioid withdrawal? Trends Pharmacol Sci 18: 134-140.
13. Couceyro P, Douglass J (1995). Precipitated morphine withdrawal stimulates multiple activator protein-1 signaling pathways in rat brain. Mol Pharmacol 47: 29-39.
14. Fellin T, Carmignoto G (2004). Neurone-to-astrocyte signalling in the brain represents a distinct multifunctional unit. J Physiol 559(Part 1): 3-15.
15. Ferguson SM, Fasano S, Yang P, Brambilla R, Robinson TE (2006). Knockout of ERK1 enhances cocaine-evoked immediate early gene expression and behavioral plasticity. Neuropsychopharma-cology 31: 2660-2668.
16. Fink DJ, DeLuca NA, Goins WF, Glorioso JC (1996). Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci 19: 265-287.
17. Fishbain DA, Rosomoff HL, Rosomoff RS (1992). Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 8: 77-85.
18. Gellert VF, Holtzman SG (1978). Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205: 536-546.
19. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC et al (2007). Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 27: 6006-6018.
20. Halassa MM, Fellin T, Haydon PG (2007). The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13: 54-63.
21. Hao S, Hu J, Fink DJ (2009). Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain. Behav Brain Res 197: 84-89.
22. Hao S, Mamiya K, Takahata O, Iwasaki H, Mata M, Fink DJ (2003a). Nifedipine potentiates the antinociceptive effect of endomorphin-1 microinjected into the periaqueductal gray in rats. Anesth Analg 96: 1065-1071; table of contents.
23. Hao S, Mata M, Glorioso JC, Fink DJ (2007). Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 14: 1010-1016.
24. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ (2003b). HSV-mediated gene transfer of the glial cell-derived neuro-trophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther 8: 367-375.
25. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ (2005). Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 57: 914-918.
26. Hao S, Takahata O, Mamiya K, Iwasaki H (2002). Sevoflurane suppresses noxious stimulus-evoked expression of Fos-like immunoreactivity in the rat spinal cord via activation of endogenous opioid systems. Life Sci 71: 571-580.
27. Harris GC, Aston-Jones G (1994). Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 371: 155-157. (Pubitemid 24284013)
28. Haydon PG, Blendy J, Moss SJ, Rob Jackson F (2009). Astrocytic control of synaptic transmission and plasticity: a target for drugs of abuse? Neuropharmacology 56(Suppl 1): 83-90.
29. Hofford RS, Hodgson SR, Roberts KW, Bryant CD, Evans CJ, Eitan S (2009). Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal. Behav Pharmacol 20: 576-583.
30. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR (2007). Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World J 7: 98-111.
31. Hutchinson MR, Lewis SS, Coats BD, Skyba DA, Crysdale NY, Berkelhammer DL et al (2009). Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 23: 240-250.
32. Ino Y, Saeki Y, Fukuhara H, Todo T (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12: 643-652.
33. Johannessen M, Delghandi MP, Moens U (2004). What turns CREB on? Cell Signal 16: 1211-1227.
34. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J et al (2004). A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24: 7353-7365.
35. Kirby KC, Stitzer ML, Heishman SJ (1990). Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II. J Pharmacol Exp Ther 255: 730-737.
36. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
37. Lane-Ladd SB, Pineda J, Boundy VA, Pfeuffer T, Krupinski J, Aghajanian GK et al (1997). CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci 17: 7890-7901.
38. Laorden ML, Nunez C, Almela P, Milanes MV (2002). Morphine withdrawal-induced c-fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones. J Neurochem 83: 132-140.
39. Laschka E, Teschemacher H, Mehraein P, Herz A (1976). Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia 46: 141-147.
40. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW (2007a). Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Invest Drugs 16: 935-950.
41. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI et al (2007b). The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2: 279-291.
42. Lewis S, Hutchinson M, Coats B, Brzeski A, Maier S, Watkins L et al (2006). AV411, a blood-brain barrier permeable glial activation inhibitor, reduces morphine withdrawal behaviors in rats. Proc Soc Neurosci: 765: 762.
43. Liu JG, Anand KJ (2001). Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 38: 1-19.
44. Lu Y, McNearney TA, Wilson SP, Yeomans DC, Westlund KN (2008). Joint capsule treatment with enkephalin-encoding HSV-1 recombinant vector reduces inflammatory damage and behavioural sequelae in rat CFA monoarthritis. Eur J Neurosci 27: 1153-1165.
45. Maldonado R, Blendy JA, Tzavara E, Gass P, Roques BP, Hanoune J et al (1996). Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 273: 657-659.
46. Maldonado R, Stinus L, Gold LH, Koob GF (1992). Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261: 669-677.
47. Mao J, Sung B, Ji RR, Lim G (2002). Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 22: 8312-8323.
48. Martin F, Laorden ML, Milanes MV (2009). Morphine withdrawal regulates phosphorylation of cAMP response element binding protein (CREB) through PKC in the nucleus tractus solitarius-A2 catecholaminergic neurons. J Neurochem 110: 1422-1432.
49. Mata M, Hao S, Fink DJ (2008). Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha. Neurosci Lett 437: 209-213.
50. McPhie AA, Barr GA (2009). Regional Fos expression induced by morphine withdrawal in the 7-day-old rat. Dev Psychobiol 51: 544-552.
51. Muller DL, Unterwald EM (2004). In vivo regulation of extracellular signal-regulated protein kinase (ERK) and protein kinase B (Akt) phosphorylation by acute and chronic morphine. J Pharmacol Exp Ther 310: 774-782.
52. Nakagawa T, Satoh M (2004). Involvement of glial glutamate transporters in morphine dependence. Ann N Y Acad Sci 1025: 383-388.
53. Natsume A, Mata M, Goss J, Huang S, Wolfe D, Oligino T et al (2001). Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol 169: 231-238.
54. Nestler EJ (2001). Molecular neurobiology of addiction. Am J Addict 10: 201-217.
55. Nestler EJ (2004). Molecular mechanisms of drug addiction. Neuropharmacology 47(Suppl 1): 24-32.
56. Nestler EJ (2005). Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.
57. Nestler EJ, Aghajanian GK (1997). Molecular and cellular basis of addiction. Science 278: 58-63.
58. Nunez C, Castells MT, Laorden ML, Milanes MV (2008). Regulation of extracellular signal-regulated kinases (ERKs) by naloxone-induced morphine withdrawal in the brain stress system. Naunyn Schmiedebergs Arch Pharmacol 378: 407-420.
59. Nunez R, Ackermann M, Saeki Y, Chiocca A, Fraefel C (2001). Flow cytometric assessment of transduction efficiency and cytotoxi-city of herpes simplex virus type 1-based amplicon vectors. Cytometry 44: 93-99.
60. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: Sydney.
61. Peng XM, Zhou ZG, Glorioso JC, Fink DJ, Mata M (2006). Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 59: 843-851.
62. Perea G, Navarrete M, Araque A (2009). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32: 421-431.
63. Pickering M, Cumiskey D, O'Connor JJ (2005). Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90: 663-670.
64. Raghavendra V, Rutkowski MD, DeLeo JA (2002). The role of spinal neuroimmune activation in morphine tolerance/hyper-algesia in neuropathic and sham-operated rats. J Neurosci 22: 9980-9989.
65. Raghavendra V, Tanga FY, DeLeo JA (2004). Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propen-tofylline in rats. Neuropsychopharmacology 29: 327-334.
66. Ren X, Noda Y, Mamiya T, Nagai T, Nabeshima T (2004). A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase. Behav Brain Res 152: 243-250.
67. Schafers M, Sommer C (2007). Anticytokine therapy in neuropathic pain management. Expert Rev Neurother 7: 1613-1627.
68. Shavit Y, Wolf G, Goshen I, Livshits D, Yirmiya R (2005). Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 115: 50-59.
69. Shaw-Lutchman TZ, Barrot M, Wallace T, Gilden L, Zachariou V, Impey S et al (2002). Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J Neurosci 22: 3663-3672.
70. Song P, Zhao ZQ (2001). The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39: 281-286.
71. Stinus L, Le Moal M, Koob GF (1990). Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37: 767-773.
72. Stornetta RL, Norton FE, Guyenet PG (1993). Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats. Brain Res 624: 19-28.
73. Taylor DA, Fleming WW (2001). Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 297: 11-18.
74. Trang T, Sutak M, Quirion R, Jhamandas K (2003). Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal. Br J Pharmacol 140: 295-304.
75. Valjent E, Pages C, Herve D, Girault JA, Caboche J (2004). Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 19: 1826-1836.
76. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP (2001). Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13: 1816-1824.
77. Volterra A, Meldolesi J (2005). Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6: 626-640.
78. Wei E, Loh H (1976). Physical dependence of opiate-like peptides. Science 193: 1262-1263.
79. Widnell KL, Russell DS, Nestler EJ (1994). Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proc Natl Acad Sci USA 91: 10947-10951.
80. Williams JT, Christie MJ, Manzoni O (2001). Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81: 299-343.
81. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC (1999). Antihyperalgesic effects of infection with a preproenke-phalin-encoding herpes virus. Proc Natl Acad Sci USA 96: 3211-3216.
82. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R et al. (2010) Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 16: 592-597; 591 following 597.
83. Yeomans DC, Jones T, Laurito CE, Lu Y, Wilson SP (2004). Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin. Mol Ther 9: 24-29.
84. Yeomans DC, Wilson SP (2009). Herpes virus-based recombinant herpes vectors: gene therapy for pain and molecular tool for pain science. Gene Ther 16: 502-508.
85. Zhang RX, Li A, Liu B, Wang L, Ren K, Zhang H et al (2008). IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 135: 232-239.